These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12236477)

  • 21. [Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice].
    Mullner K; Molnar B; Tulassay Z
    Orv Hetil; 2007 Mar; 148(12):543-51. PubMed ID: 17444020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenomics of proton pump inhibitors.
    Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
    Pharmacogenomics; 2004 Mar; 5(2):181-202. PubMed ID: 15016609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proton pump inhibitors--their pharmacological impact on the clinical management of acid-related disorders.
    Klotz U
    Arzneimittelforschung; 2009; 59(6):271-82. PubMed ID: 19634508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
    Andersson T
    Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [All proton pump inhibitors are equally efficacious in standard dosages].
    Hellström PM; Vitols S
    Lakartidningen; 2003 Jun; 100(25):2212-6. PubMed ID: 12872509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
    Edwards SJ; Lind T; Lundell L
    Aliment Pharmacol Ther; 2006 Sep; 24(5):743-50. PubMed ID: 16918878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis.
    Edwards SJ; Lind T; Lundell L
    Aliment Pharmacol Ther; 2001 Nov; 15(11):1729-36. PubMed ID: 11683686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
    Kromer W
    Scand J Gastroenterol Suppl; 2001; (234):3-9. PubMed ID: 11768559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review article: drug interactions with agents used to treat acid-related diseases.
    Humphries TJ; Merritt GJ
    Aliment Pharmacol Ther; 1999 Aug; 13 Suppl 3():18-26. PubMed ID: 10491725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetics of response to proton pump inhibitor therapy: clinical implications.
    Dickson EJ; Stuart RC
    Am J Pharmacogenomics; 2003; 3(5):303-15. PubMed ID: 14575519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
    Sugimoto M; Furuta T; Shirai N; Nakamura A; Kajimura M; Hishida A; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2005 Apr; 77(4):302-11. PubMed ID: 15903128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.
    Andersson T; Hassan-Alin M; Hasselgren G; Röhss K; Weidolf L
    Clin Pharmacokinet; 2001; 40(6):411-26. PubMed ID: 11475467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct effects of proton pump inhibitors on histamine release from rat enterochromaffin-like cells.
    Yokota T; Matsui H; Matsuura B; Maeyama K; Onji M
    Eur J Pharmacol; 2003 Nov; 481(2-3):233-40. PubMed ID: 14642791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.
    Sim SC; Risinger C; Dahl ML; Aklillu E; Christensen M; Bertilsson L; Ingelman-Sundberg M
    Clin Pharmacol Ther; 2006 Jan; 79(1):103-13. PubMed ID: 16413245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review article: the pharmacology of rabeprazole.
    Williams MP; Pounder RE
    Aliment Pharmacol Ther; 1999 Aug; 13 Suppl 3():3-10. PubMed ID: 10491723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
    Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P
    Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor.
    VandenBranden M; Ring BJ; Binkley SN; Wrighton SA
    Pharmacogenetics; 1996 Feb; 6(1):81-91. PubMed ID: 8845864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenetics of the proton pump inhibitors: a systematic review.
    Chong E; Ensom MH
    Pharmacotherapy; 2003 Apr; 23(4):460-71. PubMed ID: 12680476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.